Growth Factors

Rising Cancer Prevalence and Expanding Clinical Trial Activity

The number of people developing different types of cancer such as lung and prostate cancer in the world has been rising at an alarming rate. It was estimated by the World Health Organization (WHO) that in 2022 worldwide there were 20 million new cases of cancer and about 9.7 million cancer-related deaths with nearly 53.5 million individuals living with cancer within the past five years. The estimates in the United States, alone, project 2,001,140 cancer cases and 611,720 cancer deaths in the year 2024. This has caused an increase in the disease burden that has led life science industries to invest more in clinical research to find superior diagnostic systems and methodologies of finding effective treatment solutions. WHO data also brings out the fact that in 2024, approximately 5,306 clinical trials against malignancies neoplasms were registered around the world indicating a rise by 16.7 percent in 2010. Accordingly, the increased levels of cancer incidences, along with the overall upward trend of clinical trials in oncology, will further drive market expansion.

Restrainting Factors

High Costs and Lengthy Timelines of Oncology Clinical Trials

Oncology clinical trials are usually associated with high costs and time losses, therefore, they hinder market growth. The multifaceted nature of the cancer research demands large-scale patient enrolment, specialist infrastructure, and state of the art diagnostic equipment, and this leads to the huge eastward expansion of the cost of operations. Additionally, clinical trials in oncology tend to have multiple stages and the duration covers decades in order to evaluate the effectiveness and safety of the test which can increase the time frame on average by many years. A stringent moral guideline and mandatory endorsement also lead to delays and makes trials expensive in terms of using resources and time. This level of expenses and duration can act as repellent to the smaller companies in pharmaceutical as well as biotechnology industries dampening the potential development of the oncology clinical trials market in general.

By Phase

Phase III to Occupy Major Share of 42.00% in the Market during the Forecast Period

This dominance has largely been attributed to the rising number of Phase III trials being registered each year and the fact that this type of trial has a longer life hence playing a prominent role in market influence as well. According to the data of the World Health Organization (WHO), in 2024, there were almost 418 Phase III studies in malignant neoplasms registered worldwide, which showed an exceptional growth of 114.4 percent compared to 2000. This along with the stringent criteria put in place involving the patient enrollment, complications of measuring the efficacy, and the long-term follow-ups serve to further justify the segment dominance.

By Study Design

Interventional studies to Occupy Major Share of 37.47% in the Market during the Forecast Period

Interventional studies have taken the center stage with regards to assessing the safety and effectiveness of new modalities of treatment against cancer in controlled situations. The trials create a measurement procedure of a successful treatment through the efforts of the participants in particular interventions. This is important in design, more so in oncology setting, where the evaluation of treatment effect (response), and survival outcome is important in meeting regulatory approval. The larger pipeline of new drug candidates, and high drug investment in targeted treatment and cure take more cancer drugs, especially immuno-oncology solutions, further reinforces the positioning of interventional studies within the business arena, therefore clarifying the power of interventional studies in the innovative treatment of cancer. 

By Geography

North America Region to Occupy Major Share of 38.00% the Market during the Forecast Period

The North American market of oncology clinical trials controls the global market of oncology clinical trials due to the developed healthcare infrastructure, high regulatory efficiency, and the R&D investments in the sphere of cancer treatment. The companies and organizations are among the leading pharmaceutical and biotechnology firms in the area, and the excellence of research institutions of the world gave a contribution to the invention of oncology cures. More trial activities are encouraged by the presence of good government policies such as the existence of favorable government policies towards financing through the National Cancer Institute (NCI) based government programs, and the fact that there are several cases of cancer. Further, robust patient recruitment networks, mainstreaming of precision medicine and access to newest and advanced technologies can promise faster and more efficient implementation of trials and North America would be the market leader.

List Of Top Players

• Pfizer Inc
• Roche Holding AG
• Novartis AG
• ASTRAZENECA PLC
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Lingerie Group
• Sanofi S.A.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc

Key Industry Developments

• To be launched in June 2024, the reason is that IQVIA Inc. has introduced a new digital solution, One Home for Sites, uniting multiple applications and portals in one digital environment. This enables the clinical research sites to improve their operations and deal with tasks more effectively.
• In July 2024 Thermo Fisher Scientific Inc. has collaborated with the National Cancer Institute (NCI) to advance the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.
• In March 2023, Bayer AG partnered up with Thermo Fisher Scientific Inc. to develop NGS-based companion diagnostic (CDx) assays.

Table Of Contents

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. MARKET INTRODUCTION
   2. MARKET DRIVERS
   3. MARKET RESTRAINTS
   4. FUTURE OPPORTUNITIES
   5. MARKET TRENDS
   6. PORTER’S FIVE FORCES ANALYSIS
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Suppliers
      4. Bargaining Power of Buyers
      5. Intensity of Competitive Rivalry
   7. VALUE CHAIN & PROFIT MARGIN ANALYSIS
   8. PRICING ANALYSIS
   9. REGULATORY FRAMEWORK
   10. COVID-19 IMPACT ANALYSIS
   11. PRODUCT LIFE CYCLE ANALYSIS
   12. PESTLE ANALYSIS
   13. MICRO ECONOMIC ANALYSIS
   14. Market Lung Cancer Insights (Enterprise license)
       • Consumer Analysis (List of Potential Consumers)
       • Top 10 Country-Wise Import & Export Data (If Applicable)
       • Regulatory Bodies & Authorization Across the Globe
       • Key Conferences & Events: Next Two Years
       • Top Patents for The Market
5. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET REVENUE & SHARE ANALYSIS (2023-2032)
   1. By Phase
      1. Phase I        
      2. Phase II
      3. Phase III
      4. Phase IV
   2. By Study Design 
      1. Interventional
      2. Observational
      3. Expanded Access
   3. By Indication
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancer
      5. Others
   4. By Sponsor Type
      1. Pharmaceutical and Biotech Companies
      2. Academic and Research Institutes
      3. Government Organizations
      4. Others
6. GLOBAL ONCOLOGY CLINICAL TRIALS MARKET REVENUE & SHARE ANALYSIS (2023-2032), BY REGION
   1. NORTH AMERICA 
      1. U.S.
      2. Canada
      3. Mexico
   2. EUROPE
      1. Germany
      2. UK
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. ASIA PACIFIC 
      1. China
      2. Japan
      3. India
      4. South Korea
      5. Rest of APAC
   4. MIDDLE EAST & AFRICA
      1. GCC
      2. South Africa
      3. Rest of MEA
   5. LATIN AMERICA
      1. Brazil
      2. Argentina
      3. Rest of LATAM

For all the segments and sub-segments, Qualitative as well as Quantitative data will be provided. In Quantitative we provide the historic (2023), base (2024), estimated (2025) and forecasted (2025-2032) market value in USD Million, Share in % with a CAGR (2025-2032). This data would be provided on a regional as well as country level.

1. COMPETITIVE LANDSCAPE
   1. OVERVIEW
   2. KEY PLAYERS MARKET SHARE ANALYSIS
   3. LIST OF KEY STRATEGIC DEVELOPMENTS 
2. COMPANY PROFILES
   1. PFIZER INC
      1. Company Overview
      2. Company Financial Insights (Total Revenue, Revenue By Business Segments, and By Region)
      3. Product Benchmarking
      4. Key Strategic Developments (Merges & Acquisitions, Partnership /Agreements/Joint Venture, Expansion, New Product Launches, and other developments)
      5. Business Strategic Overview
      6. SWOT Analysis
   2. ROCHE HOLDING AG
   3. Novartis AG
   4. ASTRAZENECA PLC
   5. MERCK & CO., INC.
   6. BRISTOL-MYERS SQUIBB COMPANY
   7. JOHNSON & JOHNSON
   8. LINGERIE GROUP
   9. SANOFI S.A.
   10. GLAXOSMITHKLINE PLC
   11. ELI LILLY AND COMPANY
   12. AMGEN INC
3. LIST OF SOURCES

DISCLAIMER